US · TMDX
TransMedics Group, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Andover, MA 01810
- Website
- transmedics.com
Price · as of 2025-12-31
$100.01
Market cap 4.96B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $128.32 | +28.31% |
| Intrinsic Value(DCF) | $4,106.56 | +4,006.15% |
| Graham-Dodd Method(GD) | $41.57 | -58.44% |
| Graham Formula(GF) | $244.70 | +144.68% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $15.51 | $29.71 | $1,300.85 | $0.00 | $0.00 |
| 2020 | $36.22 | $36.80 | $8.71 | $0.00 | $0.00 |
| 2021 | $17.87 | $28.83 | $0.68 | $0.00 | $0.00 |
| 2022 | $71.52 | $73.09 | $14,477.51 | $0.21 | $0.00 |
| 2023 | $83.75 | $113.87 | $1,082,006.52 | $0.00 | $0.00 |
| 2024 | $67.46 | $302.27 | $1,119,594.64 | $11.87 | $93.20 |
| 2025 | $147.00 | $128.32 | $52,964.92 | $41.57 | $244.70 |
AI valuation
Our deep-learning model estimates TransMedics Group, Inc.'s (TMDX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $128.32
- Current price
- $100.01
- AI upside
- +28.31%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4,106.56
+4,006.15% upside
Graham-Dodd
$41.57
-58.44% upside
Graham Formula
$244.70
+144.68% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TMDX | TransMedics Group, Inc. | $100.01 | 4.96B | +28% | +4,006% | -58% | +145% | 26.26 | 10.56 | 8.25 | 33.53 | 6.87 | 10.87 | 59.92% | 17.93% | 31.43% | 54.24% | 25.12% | 20.33% | 0.99 | 7.88 | 7.14 | 6.41 | -0.13 | 38218.00% | 3713.00% | -26504.00% | 2.67% | 2.16 | 30.90% | 0.00% | 0.00% | 4.01% | 45.85 | 37.27 | 8.22 | 6.19 |
| AKRO | Akero Therapeutics, Inc. | $54.65 | 4.5B | — | — | — | — | -11.22 | 3.77 | — | -7.43 | -37.70 | 3.77 | 0.00% | — | — | -39.22% | -1042.60% | -35.85% | 0.05 | -61.14 | 19.38 | 18.69 | 1.06 | 2976.00% | — | 5898.00% | -8.17% | -5.79 | -844.19% | 0.00% | 0.00% | 3.41% | -7.43 | -9.18 | — | 20.91 |
| BRKR | Bruker Corporation | $40.11 | 6.09B | -2% | -60% | -66% | — | 206.96 | 2.44 | 1.76 | 17.43 | — | -7.46 | 45.61% | 6.30% | -0.25% | 1.37% | 2.20% | 0.48% | 0.76 | 4.69 | 1.73 | 0.66 | 3.59 | -11974.00% | 208.00% | -6816.00% | 0.72% | 0.10 | 1.10% | 0.38% | 78.10% | 8.68% | 35.15 | 175.83 | 2.22 | 1.82 |
| GKOS | Glaukos Corporation | $120.40 | 6.99B | -42% | +3% | — | — | -51.83 | 10.56 | 13.65 | -45.16 | -281.48 | 15.48 | 55.72% | -39.33% | -36.99% | -18.78% | -36.24% | -14.31% | 0.21 | -43.06 | 4.69 | 3.82 | -0.32 | 1841.00% | 3233.00% | -2013.00% | -0.78% | -0.46 | -10.09% | 0.00% | 0.00% | 0.00% | -34.01 | -125.68 | 13.38 | 16.38 |
| HNGE | Hinge Health, Inc. | $42.76 | 3.37B | +11% | +616% | — | — | -6.72 | 9.38 | 6.04 | -5.91 | -0.20 | 11.39 | 79.65% | -92.94% | -89.86% | -132.86% | 6793.55% | -74.51% | 0.02 | — | 1.47 | 1.19 | 0.37 | 336000.00% | 5058.00% | 27749.00% | 4.81% | 0.47 | -2122.88% | 0.00% | 0.00% | 1.83% | -5.85 | 18.72 | 5.44 | 2.49 |
| IMVT | Immunovant, Inc. | $27.73 | 5.64B | — | — | — | — | -6.14 | 3.59 | — | -4.18 | -13.59 | 3.59 | 0.00% | — | — | -62.46% | 3667.16% | -57.36% | 0.00 | — | 11.16 | 10.42 | 1.63 | 4521.00% | — | 7552.00% | -14.82% | -5.47 | 3152.27% | 0.00% | 0.00% | 3.09% | -4.17 | -4.85 | — | 19.16 |
| INDV | Indivior Pharmaceuticals … | $32.72 | 4.08B | +249% | +42% | -77% | -38% | 19.04 | -40.38 | 3.23 | 12.71 | 0.18 | -39.58 | 80.23% | 21.15% | 16.95% | -93.96% | -87.53% | 16.67% | -0.62 | 5.82 | 0.71 | 0.49 | -0.44 | 1083333.00% | 429.00% | -142857.00% | -2.33% | -0.03 | 35.36% | 0.00% | 0.00% | 5.03% | 14.75 | -41.54 | 3.12 | 3.05 |
| KYMR | Kymera Therapeutics, Inc. | $91.35 | 7.31B | -43% | -53% | -100% | -68% | -24.42 | 4.81 | 193.97 | -22.56 | -102.50 | 4.81 | 100.00% | -891.33% | -794.39% | -25.78% | -55.98% | -22.89% | 0.05 | -1403.21 | 10.47 | 10.19 | 0.91 | 2383.00% | -1672.00% | 1302.00% | -3.08% | -2.80 | -37.55% | 0.00% | 0.00% | 3.19% | -19.57 | -29.18 | 174.43 | 27.01 |
| NAMS | NewAmsterdam Pharma Compa… | $35.46 | 4.08B | +16% | -57% | — | +102% | — | 5.50 | 166.90 | -12.87 | — | 5.50 | 99.74% | -1002.90% | -905.74% | 0.00% | 1564.53% | 0.00% | 0.00 | — | 7.88 | 7.69 | 2.02 | -3164.00% | -5061.00% | -704.00% | -3.94% | -1.72 | 1026.20% | 0.00% | — | 0.00% | -13.82 | -21.07 | 138.63 | 24.84 |
| OPCH | Option Care Health, Inc. | $32.46 | 5.27B | +26% | -61% | -85% | -17% | 24.09 | 3.77 | 0.89 | 10.05 | 592.65 | -16.55 | 19.26% | 5.98% | 3.67% | 15.20% | 15.01% | 6.04% | 0.00 | 2.70 | 1.53 | 0.85 | -0.49 | 407.00% | 1303.00% | -1019.00% | 5.17% | 0.31 | 15.65% | 0.00% | 0.00% | 26.95% | 14.11 | 18.45 | 0.84 | 3.52 |
| OSCR | Oscar Health, Inc. | $13.64 | 3.54B | +238% | +3,520% | — | — | -8.28 | 3.75 | 0.31 | -0.28 | — | 3.75 | 14.38% | -3.39% | -3.79% | -44.49% | 23.17% | -7.93% | 0.44 | -22.52 | 0.95 | 0.91 | 5.99 | -186594.00% | 2750.00% | 1138.00% | 28.86% | 0.23 | -61.87% | 0.00% | 0.00% | 30.44% | -0.27 | 0.10 | 0.01 | 1.28 |
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- CEO
- Waleed H. Hassanein
- Employees
- 728
- Beta
- 1.98
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4,106.56 ÷ $100.01) − 1 = +4,006.15% (DCF, example).